Accuracy of B-GGT Fraction for the Diagnosis of Non-alcoholic Fatty Liver Disease
Overview
Authors
Affiliations
Background: Serum gamma-glutamyltransferase (GGT) activity is a sensitive but non-specific marker of non-alcoholic fatty liver disease (NAFLD). Recently, four GGT fractions (big-, medium-, small-, free-GGT) were described in humans.
Aim: We aimed to investigate whether a specific GGT fraction pattern is associated with NAFLD.
Methods: Gamma-glutamyltransferase fractions were determined in patients with NAFLD (n = 90), and compared with those in control subjects (n = 70), and chronic hepatitis C (CHC, n = 45) age and gender matched.
Results: Total GGT was elevated in NAFLD as compared to controls (median, 25°-75° percentile: 39.4, 20.0-82.0 U/L vs. 18.4, 13.2-24.9 U/L respectively, P < 0.001). All fractions were higher in NAFLD than in controls (P < 0.001). The b-GGT showed the highest diagnostic accuracy for NAFLD diagnosis [area under ROC curve (ROC-AUC): 0.85; cut-off 2.6 U/L, sensitivity 74%, specificity 81%]. Also subjects with CHC showed increased GGT (41.5, 21.9-84.5 U/L, P < 0.001 vs. controls, P = n.s. vs. NAFLD), as well as m-, s-, and f-GGT, while b-GGT did not show any significant increase (P = n.s. vs. HS, P < 0.001 vs. NAFLD). In subjects with CHC, s-GGT showed the best diagnostic value (ROC-AUC: 0.853; cut-off 14.1 U/L, sensitivity 73%, specificity 90%). Serum GGT did not show any value in the differential diagnosis between NAFLD and CHC (ROC-AUC 0.507, P = n.s.), while b-GGT/s-GGT ratio showed the highest diagnostic accuracy for distinguishing NAFLD and CHC (ROC-AUC: 0.93; cut-off value 0.16, sensitivity 82%, specificity 90%).
Conclusions: b-GGT increases in NAFLD, but not in CHC. GGT fraction analysis might help in improving the sensitivity and specificity of the diagnosis of NAFLD and other liver dysfunctions.
Extracellular vesicles and glycans: new avenue for biomarker research.
Jankovic T, Jankovic M Biochem Med (Zagreb). 2024; 34(2):020503.
PMID: 38882582 PMC: 11177654. DOI: 10.11613/BM.2024.020503.
Thoughts on Non-Alcoholic Fatty Liver Disease and Chronic Disease.
Pizzorno J, Pizzorno L Integr Med (Encinitas). 2023; 22(2):6-9.
PMID: 37363148 PMC: 10289108.
Zhu W, Shi P, Fu J, Liang A, Zheng T, Wu X Lipids Health Dis. 2022; 21(1):149.
PMID: 36585668 PMC: 9804963. DOI: 10.1186/s12944-022-01752-5.
Bullon-Vela V, Xu Y, Razquin C, Abete I, Zulet M, Martinez-Gonzalez M Food Funct. 2022; 14(2):1011-1023.
PMID: 36562455 PMC: 9870039. DOI: 10.1039/d2fo02846h.
Lin H, Zhou X, Zhang Z Contrast Media Mol Imaging. 2022; 2022:7737610.
PMID: 35949700 PMC: 9348969. DOI: 10.1155/2022/7737610.